Andrew W Artenstein1, Thomas L Higgins, Steven M Opal. 1. 1Department of Medicine, Baystate Health and Tufts University School of Medicine, Springfield, MA. 2Division of Infectious Diseases, Memorial Hospital of Rhode Island and the Alpert Medical School of Brown University, Providence, RI.
Abstract
HYPOTHESIS: The therapeutic approach to sepsis is following an evolutionary process of scientific discovery as articulated in the landmark work by Kuhn, The Structure of Scientific Revolutions, first published 50 years ago. BACKGROUND: Incremental advances, beginning with the introduction of antimicrobials and most recently highlighted by revised, evidence-based guidelines for the management of sepsis, have been accompanied by episodic paradigm shifts. Although some of these have shown success, there are numerous, noteworthy failures, largely involving immune- and coagulation-based therapeutic strategies. CONCLUSION: A sustained paradigm shift in the approach to treating sepsis has yet to emerge, but recent data suggest that an open-minded posture informed by novel pathobiologic findings may eventually bear fruit.
HYPOTHESIS: The therapeutic approach to sepsis is following an evolutionary process of scientific discovery as articulated in the landmark work by Kuhn, The Structure of Scientific Revolutions, first published 50 years ago. BACKGROUND: Incremental advances, beginning with the introduction of antimicrobials and most recently highlighted by revised, evidence-based guidelines for the management of sepsis, have been accompanied by episodic paradigm shifts. Although some of these have shown success, there are numerous, noteworthy failures, largely involving immune- and coagulation-based therapeutic strategies. CONCLUSION: A sustained paradigm shift in the approach to treating sepsis has yet to emerge, but recent data suggest that an open-minded posture informed by novel pathobiologic findings may eventually bear fruit.
Authors: Leland Shapiro; Sias Scherger; Carlos Franco-Paredes; Amal A Gharamti; David Fraulino; Andrés F Henao-Martinez Journal: Front Pharmacol Date: 2022-06-23 Impact factor: 5.988
Authors: David N Hager; Michael H Hooper; Gordon R Bernard; Laurence W Busse; E Wesley Ely; Alpha A Fowler; David F Gaieski; Alex Hall; Jeremiah S Hinson; James C Jackson; Gabor D Kelen; Mark Levine; Christopher J Lindsell; Richard E Malone; Anna McGlothlin; Richard E Rothman; Kert Viele; David W Wright; Jonathan E Sevransky; Greg S Martin Journal: Trials Date: 2019-04-05 Impact factor: 2.279
Authors: Christopher J Lindsell; Anna McGlothlin; Samuel Nwosu; Todd W Rice; Alex Hall; Gordon R Bernard; Laurence W Busse; E Wesley Ely; Alpha A Fowler; David F Gaieski; Jeremiah S Hinson; Michael H Hooper; James C Jackson; Gabor D Kelen; Mark Levine; Greg S Martin; Richard E Rothman; Jonathan E Sevransky; Kert Viele; David W Wright; David N Hager Journal: Trials Date: 2019-12-04 Impact factor: 2.279
Authors: McKenzie K Hollen; Julie A Stortz; Dijoia Darden; Marvin L Dirain; Dina C Nacionales; Russell B Hawkins; Michael C Cox; Maria-Cecilia Lopez; Jaimar C Rincon; Ricardo Ungaro; Zhongkai Wang; Quran Wu; Babette Brumback; Marie-Pierre L Gauthier; Michael Kladde; Christiaan Leeuwenburgh; Mark Segal; Azra Bihorac; Scott Brakenridge; Frederick A Moore; Henry V Baker; Alicia M Mohr; Lyle L Moldawer; Philip A Efron Journal: Crit Care Date: 2019-11-13 Impact factor: 9.097